Published in J Exp Med on September 01, 1976
Direct evidence for loss of human suppressor cells during active autoimmune disease. Proc Natl Acad Sci U S A (1978) 2.32
Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A (1985) 1.97
Suppressor-cell dysfunction in systemic lupus erythematosus. Cells involved and in vitro correction. J Clin Invest (1978) 1.93
Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function. J Clin Invest (1980) 1.68
The cellular basis of the impaired autologous mixed lymphocyte reaction in patients with systemic lupus erythematosus. J Clin Invest (1979) 1.67
Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol (1983) 1.51
Reversal of nzb/nzw disease with total lymphoid irradiation. J Exp Med (1979) 1.12
Production of auto-anti-idiotypic antibody during the normal immune response: changes in the auto-anti-idiotypic antibody response and the idiotype repertoire associated with aging. Proc Natl Acad Sci U S A (1980) 1.09
Autoimmune diseases: immunopathology and etiopathogenesis. Am J Pathol (1982) 1.07
Abnormalities in clonable B lymphocytes and myeloid progenitors in autoimmune NZB mice. Proc Natl Acad Sci U S A (1979) 0.96
Studies on the mechanism of peptidoglycan- and lipopolysaccharide-induced polyclonal activation. Infect Immun (1982) 0.89
Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. Eur J Immunol (2004) 0.89
Suppressor cell decrease in alopecia areata. Arch Dermatol Res (1982) 0.87
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. J Korean Med Sci (2004) 0.85
Sex differences in the regulation of experimentally induced autoantibodies in (NZB x NZW)F1 mice. Immunology (1980) 0.78
Abnormal cellular and humoral immunity in childhood acute lymphoblastic leukemia in long-term remission. West J Med (1987) 0.75
Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome after Thymectomy for Myasthenia Gravis - A Case Report. Open Access Maced J Med Sci (2015) 0.75
Migration of carbon-laden peritoneal macrophages into the thymus of autoimmune New Zealand mice. J Anat (1989) 0.75
Sensitivity of pre-T cells to natural thymocytotoxic autoantibodies developed in New Zealand Black mice. Clin Exp Immunol (1982) 0.75
Production of migration inhibitory factor in response to bacterial and fungal antigens in patients with untreated Graves' disease. Can Med Assoc J (1980) 0.75
Proliferative responsiveness of B cells from autoimmune NZB mice to anti-immunoglobulin and interleukin-4. Clin Exp Immunol (1989) 0.75
New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis (1997) 0.75
Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet (1971) 7.98
Immunologic functions of isolated human lymphocyte subpopulations. I. Quantitative isolation of human T and B cells and response to mitogens. J Immunol (1974) 5.50
Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen. I. Characterization of the inhibitory cell activity. J Exp Med (1972) 3.80
Biological expressions of lymphocyte activation. II. Generation of a population of thymus-derived suppressor lymphocytes. J Exp Med (1973) 3.50
Biological expressions of lymphocyte activation. 3. Suppression of plaque-forming cell responses in vitro by supernatant fluids from concanavalin A-activated spleen cell cultures. J Immunol (1974) 3.27
Decline in suppressor T cell function with age in female NZB mice. J Immunol (1974) 2.79
Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45
Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen. II. Evidence for separate stimulatory and inhibitory cells. J Exp Med (1973) 2.33
Biological expressions of lymphocyte activation : I. Effects of phytomitogens on antibody synthesis in vitro. J Exp Med (1973) 1.83
Mechanism of allograft rejection in New Zealand mice. I. Cell synergy and its age-dependent loss. J Immunol (1973) 1.59
Induction of immunologic tolerance in older New Zealand mice repopulated with young spleen, bone marrow, or thymus. J Exp Med (1970) 1.58
Strain differences in the immune responses of mice. 3. A raised tolerance threshold in NZB thymus cells. Immunology (1971) 1.57
Biological expressions of lymphocyte activation. IV. Concanavalin A-activated suppressor cells in mouse mixed lymphocyte reactions. J Immunol (1975) 1.54
Pathogenesis of autoimmunity in New Zealand mice. V. Loss of thymic suppressor function. Arthritis Rheum (1974) 1.42
Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol (1973) 1.40
Regulation of the antibody response to type 3 pneumococcal polysaccharide. 3. Role of regulatory T cells in the development of an IgG and IgA antibody response. J Immunol (1974) 1.34
Immunofluorescence studies on thymocytotoxic antibody from New Zealand Black mice. J Immunol (1974) 1.31
Thymosin corrects the abnormal DNA synthetic response of NZB mouse thymocytes. Proc Natl Acad Sci U S A (1974) 1.19
Increased survival of NZB-W mice given multiple syngeneic young thymus grafts. Clin Immunol Immunopathol (1973) 1.13
Correction of T cell function by thymosin in New Zealand mice. J Immunol (1974) 0.98
Mechanism of allograft rejection in New Zealand mice. II. Role of a serum factor. J Immunol (1974) 0.90
Effect of concanavalin A on immunologic abnormalities of New Zealand (NZB/W) mice. Int Arch Allergy Appl Immunol (1975) 0.81
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med (2001) 8.69
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
Metabolism of immunoglobulins. Prog Allergy (1969) 5.74
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest (1998) 5.70
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell (1995) 5.64
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature (2011) 5.41
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature (1981) 4.87
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A (1989) 4.22
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A (1985) 3.74
Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A (1981) 3.73
Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. Nature (1981) 3.64
Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med (1998) 3.50
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest (1972) 3.43
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science (1986) 3.32
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Protein-losing enteropathy. Gastroenterology (1966) 3.21
T-cell regulation of murine IgA synthesis. J Exp Med (1979) 3.11
Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy. J Clin Invest (1972) 3.09
The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med (1967) 3.06
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol (1999) 2.92
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism. J Clin Invest (1966) 2.91
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest (1972) 2.88
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A (2000) 2.80
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.79
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
Variable amplification of immunoglobulin lambda light-chain genes in human populations. Nature (1983) 2.75
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med (1996) 2.68
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1976) 2.65
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol (1983) 2.65
NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med (1992) 2.62
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet (1968) 2.61
NIH conference. New insights into common variable immunodeficiency. Ann Intern Med (1993) 2.52
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.51
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol (1993) 2.48
The mechanism of appearance of immunoglobulin A in nasal secretions in man. J Clin Invest (1967) 2.45
Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol (2001) 2.42
Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J Exp Med (1996) 2.38
Selective loss of suppressor cell function in New Zealand mice induced by NTA. J Immunol (1977) 2.38
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol (1997) 2.35
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A (1998) 2.33
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 2.30
Dermatitis herpetiformis: the skin and the gut. Ann Intern Med (1980) 2.24
IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity (1996) 2.23
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A (1989) 2.23
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A (1987) 2.22
Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. J Immunol Methods (1980) 2.21
Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol (1984) 2.20
An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med (1999) 2.20
Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. Proc Natl Acad Sci U S A (2003) 2.20
The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med (1996) 2.17
Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature (1998) 2.17
Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity (1995) 2.17
TNBS-colitis. Int Rev Immunol (2000) 2.17
The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J Immunol (1979) 2.15
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A (1999) 2.14
A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest (1992) 2.13
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci U S A (1986) 2.12
Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood (1997) 2.10
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. Proc Natl Acad Sci U S A (1991) 2.03
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor T cells in the murine Peyer's patch after protein feeding. J Immunol (1981) 2.03
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood (1990) 2.02
Incorporation of L-leucine-14C into immunoglobulins by jejunal biopsies of patients with celiac sprue and other gastrointestinal diseases. J Clin Invest (1971) 2.01
Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. N Engl J Med (1989) 1.99
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J Immunol (1984) 1.99
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol (1987) 1.96
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95